logo
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action

Business Wire6 days ago
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the 'Class Period'). Biohaven investors have until September 12, 2025 to file a lead plaintiff motion.
IF YOU SUFFERED A LOSS ON YOUR BIOHAVEN LTD. (BHVN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS
What Happened?
On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors.
Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025.
Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025.
Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Biohaven securities during the Class Period, you may move the Court no later than September 12, 2025 to request appointment as lead plaintiff in this putative class action lawsuit.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UnitedHealth Group's (UNH) Healthcare Dominance: A Key Player in the Dogs of the Dow
UnitedHealth Group's (UNH) Healthcare Dominance: A Key Player in the Dogs of the Dow

Yahoo

time9 minutes ago

  • Yahoo

UnitedHealth Group's (UNH) Healthcare Dominance: A Key Player in the Dogs of the Dow

UnitedHealth Group Incorporated (NYSE:UNH) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A senior healthcare professional giving advice to a patient in a clinic. The stock has dropped over 44% so far this year after reporting weaker-than-expected earnings in the first quarter. The company first reduced its full-year outlook and later chose to withdraw it entirely. Even with the underwhelming Q1 performance, UnitedHealth Group Incorporated (NYSE:UNH) still posted a 9.8% year-over-year increase in revenue, reaching $109.6 billion. It earned a profit of around $6.3 billion during the quarter and maintained a solid financial position, holding close to $34.3 billion in cash and cash equivalents, along with a debt level that remains manageable. The company has added 780,000 new members so far this year. Meanwhile, Optum Health still expects to provide value-based care to an additional 650,000 patients in 2025. In addition, UnitedHealth Group Incorporated (NYSE:UNH) generated $5.5 billion in operating cash flow during the quarter and returned $5 billion to investors through dividends and share repurchases. The company has been rewarding shareholders with growing dividends since 2011 and currently offers a quarterly dividend of $2.21 per share. The stock supports a dividend yield of 3.15%, as of July 26. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Yield-Focused Investors Favor Chevron (CVX) in the Dogs of the Dow Portfolio
Why Yield-Focused Investors Favor Chevron (CVX) in the Dogs of the Dow Portfolio

Yahoo

time9 minutes ago

  • Yahoo

Why Yield-Focused Investors Favor Chevron (CVX) in the Dogs of the Dow Portfolio

Chevron Corporation (NYSE:CVX) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. An aerial view of an oil rig at sea, the sun glinting off its structure. It is currently facing some company-specific challenges, including a complicated merger and operations in politically unstable regions. However, these issues are unlikely to affect its long-term prospects. Income-focused investors can generally feel confident investing in Chevron. Chevron Corporation (NYSE:CVX)'s integrated business model, covering everything from exploration and production to refining and chemicals, offers operational flexibility and acts as a natural hedge against fluctuations in energy prices, enhancing its resilience through market cycles. Unlike many competitors who chase volume growth, Chevron takes a disciplined approach, investing only in its highest-return projects, avoiding overexpansion during booms, and making strategic, value-adding acquisitions. This strategy, along with a strong balance sheet, establishes Chevron Corporation (NYSE:CVX) as a leading operator with the financial strength to endure downturns and seize growth opportunities. The company has been growing its dividends for 38 consecutive years and currently offers a quarterly dividend of $1.71 per share. As of July 26, the stock has a dividend yield of 4.42%. While we acknowledge the potential of CVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

Coca-Cola's (KO) Timeless Appeal Among the Dogs of the Dow
Coca-Cola's (KO) Timeless Appeal Among the Dogs of the Dow

Yahoo

time9 minutes ago

  • Yahoo

Coca-Cola's (KO) Timeless Appeal Among the Dogs of the Dow

The Coca-Cola Company (NYSE:KO) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A row of factory workers assembling bottles of sparkling soft drinks on a conveyor belt. The stock has surged by nearly 12% since the start of 2025, outperforming the broader market. Investors have shown strong interest in the stock this year for a number of reasons. It's often seen as a safe choice during market downturns because of its stability, making it a popular pick when uncertainty rises. More recently, confidence in The Coca-Cola Company (NYSE:KO) has been boosted by its strong position against potential tariff impacts. In addition, the company reported strong earnings in the second quarter of 2025. Its revenue came in at $12.6 billion, up 1% from the same period last year. The revenue beat analysts' estimates by $42 million. Operating income rose by 63%, while on a comparable currency-neutral basis (non-GAAP), it saw a 15% increase. The Coca-Cola Company (NYSE:KO) also remains investors' favorite because the company has been growing its payouts for 63 consecutive years. The company pays a quarterly dividend of $0.51 per share and has a dividend yield of 2.95%, as of July 26. While we acknowledge the potential of KO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store